Diagnostic significance of detecting neutralizing antibodies to SARS-CoV-2
Keywords:coronavirus disease, SARS-CoV-2, spike S protein, neutralizing antibodies, СOVID-19, immune response
Coronavirus disease is an infectious disease caused by a recently discovered coronavirus called SARS-CoV-2. Coronavirus disease caused by the SARS-CoV-2 continues to be the world’s greatest global challenge, both in terms of searching for treatment and prevention methods, and developing new diagnostic directions. One of the new directions of serological diagnosis is the possibility of determining neutralizing antibodies to SARS-CoV-2. This is a fully automated highly sensitive test for detecting neutralizing antibodies to RBD domain in S1, which is performed by immunochemiluminescent analysis and allows the simultaneous detection of total neutralizing antibodies (IgM + IgG) that increases the sensitivity of testing because the order of IgM and IgG antibodies is individual.
Харченко Е.П. Коронавирус SARS-Cov-2: особенности структурных белков, контагиозность и возможные иммунные коллизии. Эпидемиология и вакцинопрофилактика. 2020. 19(2). 13-30. https://doi: 10.31631/2073-3046-2020-19-2-13-30.
Robson B. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput. Biol. Med. 2020 Jun. 121. 103749. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151553. doi: 10.1016/j.compbiomed.2020.103749.
Seow J., Graham С., Doores K.J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology. 2020. Vol. 5. Р. 1598-1607. https://www.nature.com/articles/s41564-020-00813-8.
Zhou G., Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int. J. Biol. Sci. 2020. 16(10). 1718-23. Epub 2020/04/01. pmid: 32226289; PubMed Central PMCID: PMC7098029.
French M.A., Moodley Y. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times. Respirology. 2020. 25(7). 680-2. Epub 2020/05/22. pmid: 32436320; PubMed Central PMCID: PMC7280731.
Addetia A., Crawford K.H.D., Dingens A. et al. Neutralizing antibodies correlate with protection from SARS-1 CoV-2 in humans during a 2-fishery vessel outbreak with high attack rate. medRxiv preprint. 2020. https://doi.org/10.1101/2020.08.13.20173161.
Guo L. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin. Infect. Dis. 2020. https://doi.org/10.1093/cid/ciaa310.
Ni L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020. https://doi.org/10.1016/j.immuni.2020.04.023.
Yu H. et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur. Respir. J. 2020. https://doi.org/10.1183/13993003.01526-2020.
Suthar M.S. et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Reports Medicine. 2020. 1. 100040.
Robbiani D.F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020. 584. 437-442.
Houlihan C.F. et al. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. Lancet Lond. Engl. 2020. 396. e6-e7.
Chen Y. et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J. Infect. 2020. 81. 420-426.
Rudberg A.-S. et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat. Commun. 2020. 11. 5064.
Wajnberg A., Amanat F., Firpo A. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 4 Dec 2020. Vol. 370. Issue 6521. P. 1227-123. DOI: 10.1126/science.abd7728 https://science.sciencemag.org/content/370/6521/1227.
Moore J.P., Klasse P.J., Silvestri G. COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds / Editor American Society for Microbiology. DOI: 10.1128/JVI.01083-20.
Kellam Р., Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. Journal of General Virology. 2020. Vol. 101. Issue 8. https://doi.org/10.1099/jgv.0.001439.
Mo H., Zeng G., Ren X. et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. PMID: 16423201. PMCID: PMC7192223. DOI: 10.1111/j.1440-1843.2006.00783.x. https://pubmed.ncbi.nlm.nih.gov/16423201.
Petersen K.M. et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. 2020. 20. e238-e244.
Callow K.A., Parry H.F., Sergeant M., Tyrrell D.A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 1990. 105. 435-446.
Wang M. et al. Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS ONE. 2011. 6. e16809.
Wrapp D., Wang N., Corbett K.S. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 13 Mar 2020. Vol. 367. Issue 6483. Р. 1260-1263.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.